from david stat.com david dodel subject hicn medic new part cut here volum number april health info com network medic newslett editor david dodel d.m.d north nd street suit scottsdal arizona usa telephon fax compil copyright david dodel d.m.d all right reserv licens herebi grant republish electron media which fee charg so long text copyright notic licens attach intact ani all republish portion portion health info com network newslett distribut biweekli articl medic natur welcom you have articl pleas contact editor inform how submit you interest join autom distribut system pleas contact editor e mail address editor internet david stat.com fidonet bitnet atw h asuacad listserv mednew asuacad.bitnet internet mednew asuvm.inre.asu.edu anonym ftp vm nodak.edu notif list hicn notifi request stat.com fax deliveri contact editor inform t b l e o f c o n t e n t s center diseas control prevent mmwr april rate cesarean deliveri malaria among u. embassi personnel fda approv hib vaccin children infant dental new workshop explor oral manifest hiv infect food drug administr new fda approv depo provera inject contracept new rule speed approv drug life threaten ill articl research promis prevent slow blind from retin diseas affluent diet increas risk heart diseas gener announc public health profession from nation cancer institut public patient avail from nation cancer institut aid new summari aid daili summari april april aid statist worldwid aid statist hicnet medic newslett page i volum number april center diseas control prevent mmwr rate cesarean deliveri unit state sourc mmwr date apr cesarean deliveri have account nearli million approxim million annual deliveri unit state sinc tabl cesarean rate unit state third highest among report countri exceed onli brazil puerto rico report present data cesarean deliveri from cdc' nation hospit discharg survei nhd compar data previou year data discharg from short stai nonfeder hospit have been collect annual sinc nhd conduct cdc' nation center health statist medic demograph inform were abstract from sampl inpati discharg from particip hospit cesarean vagin birth after prior cesarean vbac present report base weight nation estim from nhd sampl approxim women discharg after deliveri estim number live birth type deliveri were calcul appli cesarean rate from nhd live birth from nation vital registr data therefor estim number cesarean report agre previous publish data base sole nhd state differ analysi signific confid level base two tail t test critic valu were cesarean per deliveri same rate similar rate dure tabl primari cesarean rate i. number first cesarean per deliveri women who had previou cesarean also stabl rang from cesarean rate south significantli p higher than rate west midwest northeast rate were higher mother ag greater than equal year than younger women proprietari hospit than nonprofit govern hospit hospit fewer than bed than larger hospit deliveri which blue cross blue shield other privat insur expect sourc payment than other sourc payment tabl same pattern character primari cesarean deliveri sinc earli s number percentag birth older women increas howev ag distribut mother had remain same overal cesarean rate would have been essenti same observ base nhd approxim live birth hicnet medic newslett page volum number april estim were cesarean deliveri estim birth were repeat cesarean were primari cesarean sinc approxim primari cesarean have been perform annual women who had previou cesarean deliv vagin compar all cesarean were associ previou cesarean dystocia i. failur labor progress breech present fetal distress all other specifi complic averag hospit stai all deliveri dai comparison hospit stai primari cesarean deliveri dai repeat cesarean dai nearli twice durat vbac deliveri dai vagin deliveri were vbac dai averag hospit stai all deliveri dai primari cesarean dai repeat cesarean dai vbac non vbac vagin deliveri dai respect report offic vital health statist system nation center health statist cdc editori note cesarean rate unit state steadili increas from through howev find report indic rate have been stabl sinc becaus littl evid matern child health statu ha improv dure time becaus cesarean associ increas risk complic childbirth nation health object year reduc overal cesarean rate fewer per deliveri primari cesarean rate fewer per deliveri object postpartum complic includ urinari tract wound infect mai account part longer hospit stai cesarean deliveri than vagin birth moreov prolong hospit stai cesarean deliveri substanti increas health care cost exampl averag cost cesarean vagin deliveri were respect addit cost each cesarean deliveri includ physician fee hospit charg cesarean rate had been year object instead number cesarean birth would have decreas versu result save more than billion physician fee hospit charg despit steadi increas vbac rate sinc sever factor mai imped progress toward year nation health object cesarean deliveri exampl vbac rate substanti reflect number women offer trial labor which ha been increasingli encourag sinc women who offer trial labor could deliv vagin level alreadi achiev mani hospit trial labor routin offer hospit survei most recent year which hicnet medic newslett page volum number april nation data avail when vbac rate accord nhd data year object specifi vbac rate base all women who had prior cesarean regardless whether trial labor attempt reach overal cesarean rate goal howev increas vbac rate need combin substanti reduct primari rate on hospit succeed reduc rate cesarean deliveri appli object criteria four most common indic cesarean deliveri requir second opinion institut peer review process other recommend decreas cesarean deliveri rate includ elimin incent physician hospit equal reimburs vagin cesarean deliveri public dissemin physician hospit specif cesarean deliveri rate increas public awar differ practic address malpractic concern which mai import factor maintain high rate cesarean deliveri refer notzon fc intern differ us obstetr intervent jama grave ej nch summari nation hospit discharg survei hyattsvil maryland us depart health human servic public health servic cdc advanc data taffel sm placek pj kosari cl u. cesarean section rate updat birth public health servic healthi peopl nation health promot diseas prevent object full report commentari washington dc us depart health human servic public health servic dhh public ph danforth dn cesarean section jama hospit insur associ america tabl cost matern care physician fee hospit charg censu region base consum price index sourc book health insur data washington dc hospit insur associ america committe obstetr acog committe opinion guidelin vagin deliveri after previou cesarean birth washington dc american colleg obstetrician gynecologist hicnet medic newslett page volum number april rosen mg dickinson jc vagin birth after cesarean meta analysi indic success obstet gynecol shiono ph fielden jg mcnelli d rhoad gg pears wh recent trend cesarean birth trial labor rate unit state jama myer sa gleicher n success program lower cesarean section rate n engl j med us trade name commerci sourc identif onli doe impli endors public health servic u. depart health human servic hicnet medic newslett page volum number april malaria among u. embassi personnel kampala uganda sourc mmwr date apr treatment prevent malaria africa ha becom challeng complex problem becaus increas drug resist although risk acquir malaria u. citizen depend station oversea gener ha been low risk vari substanti unpredict dure mai offic medic servic depart state om do cdc were notifi increas number malaria case among offici u. personnel station kampala uganda review health record from embassi health unit ehu kampala indic case malaria were diagnos offici personnel from march through june compar two case dure same period ehu om do cdc conduct investig confirm all report malaria case identifi potenti risk factor malaria among u. embassi personnel report summar result investig malaria blood smear from report case patient were avail review om do cdc case malaria confirm slide posit plasmodium sp person were slide confirm have malaria questionnair distribut all person serv ehu obtain inform about resid activ us malaria chemoprophylaxi us person protect measur i. us bednet insect repel have window door screen wear long sleev pant even person elig survei respond risk malaria associ sex locat resid kampala although risk malaria higher among children ag less than equal year than among person greater than year differ signific rel risk rr confid interv ci eighti two percent case occur among person who had been live kampala year compar those live less than year travel outsid kampala area more rural set associ increas risk malaria four malaria chemoprophylaxi regimen were us person who particip survei mefloquin chloroquin proguanil chloroquin alon proguanil alon addit person who respond were us ani malaria chemoprophylaxi risk malaria significantli lower among person us either mefloquin chloroquin proguanil than among person us other regimen prophylaxi rr ci twelv person us prophylaxi report side effect fear possibl side effect reason risk malaria lower among person who report us bednet hicnet medic newslett page volum number april all most time than among person who sometim rare us bednet rr ci risk malaria also lower among person who consist us insect repel even compar those who rare us repel rr upper confid limit risk malaria associ failur have window door screen wear long sleev pant even result investig ehu staff review all personnel need us compli recommend malaria chemoprophylaxi regimen ehu staff also emphas need us person protect measur made plan obtain insecticid impregn bednet provid window door screen all personnel report u. embassi health unit kampala uganda offic medic svc dept state washington d.c malaria br div parasit diseas nation center infecti diseas cdc editori note uganda increas malaria among u. personnel attribut poor adher both recommend malaria chemoprophylaxi regimen us person protect measur dure period increas malaria transmiss intensifi chloroquin resist sub saharan africa find report underscor need provid initi continu counsel regard malaria prevent person live abroad malaria endem area prevent measur also import short term travel area mefloquin effect prophylaxi regimen africa most other area chloroquin resist p falciparum howev some area e.g thailand resist mefloquin mai limit it effect africa efficaci mefloquin compar chloroquin alon prevent infect p falciparum mefloquin safe well toler when given mg per week over year period risk seriou advers reaction possibl associ mefloquin prophylaxi e.g psychosi convuls low i. episod per user while risk less sever advers reaction e.g dizzi gastrointestin complaint sleep disturb similar other antimalari chemoprophylact doxycyclin ha similar prophylact efficaci mefloquin need daili dose mai reduc complianc effect regimen chloroquin alon effect prophylaxi area intens chloroquin resist e.g southeast asia africa africa person who cannot take mefloquin doxycyclin chloroquin proguanil altern although less effect regimen chloroquin should us malaria prevent area onli where chloroquin resist p falciparum ha been report countri specif recommend prevent malaria inform hicnet medic newslett page volum number april dosag precaut malaria chemoprophylaxi regimen avail from health inform intern travel i. yellow book hour dai telephon fax refer lobel ho miani m eng t et al long term malaria prophylaxi weekli mefloquin peac corp volunt effect well toler regimen lancet world health organ review central nervou system advers event relat antimalari drug mefloquin geneva world health organ public who mal pang l limsomwong n singharaj p prophylact treatment vivax falciparum malaria low dose doxycyclin j infect di pang l limsomwong n boudreau ef singharaj p doxycyclin prophylaxi falciparum malaria lancet cdc health inform intern travel atlanta us depart health human servic public health servic dhh public cdc hicnet medic newslett page volum number april fda approv us new haemophilu b conjug vaccin combin diphtheria tetanu pertussi haemophilu b conjug vaccin infant children sourc mmwr date apr haemophilu influenza type b hib conjug vaccin have been recommend us infant sinc routin us infant vaccin ha contribut substanti declin incid hib diseas unit state vaccin against diphtheria tetanu pertussi dure infanc childhood have been administ routin unit state sinc late s ha been associ greater than reduct morbid mortal associ infect organ becaus increas number vaccin now routin recommend infant high prioriti develop combin vaccin allow simultan administr fewer separ inject food drug administr fda recent licens two new product vaccin children against diseas haemophilu b conjug vaccin tetanu toxoid conjug acthib trademark vaccin against hib diseas onli combin diphtheria tetanu toxoid whole cell pertussi vaccin dtp hib conjug vaccin tetramun trademark combin vaccin formul us vaccin children against diphtheria tetanu pertussi hib diseas acthib trademark march fda approv new haemophilu b conjug vaccin polyribosylribitol phosphat tetanu toxoid conjug prp t manufactur pasteur merieux serum et vaccin distribut acthib trademark connaught laboratori inc swiftwat pennsylvania vaccin ha been licens us infant three dose primari vaccin seri administ ag month previous unvaccin infant month ag should receiv two dose month apart previous unvaccin children month ag should receiv on dose booster dose administ month ag recommend all children previous unvaccin children month ag should receiv singl dose do requir booster more than infant receiv primari vaccin seri acthib trademark consecut dose month ag develop geometr mean titer anti haemophilu b polysaccharid antibodi greater than ug ml respons similar infant who receiv recommend seri previous licens haemophilu b conjug vaccin which efficaci ha been demonstr prospect trial two u. efficaci trial prp t were termin earli becaus concomit licensur other haemophilu b conjug vaccin hicnet medic newslett page volum number april us infant studi case invas hib diseas were detect approxim infant vaccin prp t other studi suggest efficaci prp t vaccin similar other licens hib vaccin tetramun trademark march fda approv combin diphtheria tetanu toxoid whole cell pertussi vaccin dtp haemophilu b conjug vaccin tetramun trademark avail from lederl praxi biolog pearl river new york combin two previous licens product dtp triimmunol regist manufactur lederl laboratori pearl river new york haemophilu b conjug vaccin hibtit regist manufactur praxi biolog inc rochest new york vaccin ha been licens us children ag month year protect against diphtheria tetanu pertussi hib diseas when indic vaccin dtp vaccin haemophilu b conjug vaccin coincid base demonstr co mparabl higher antibodi respons each compon two vaccin tetramun trademark expect provid protect against hib well diphtheria tetanu pertussi equival alreadi licens formul other dtp haemophilu b vaccin advisori committe immun practic acip recommend all infant receiv primari seri on licens haemophilu b conjug vaccin begin month ag booster dose ag month acip also recommend all infant receiv four dose primari seri diphtheria tetanu toxoid pertussi vaccin month ag booster dose year complet statement regard recommend us acthib trademark tetramun trademark be develop report offic vaccin research review center biolog evalu research food drug administr div immun nation center prevent svc mening special pathogen br div bacteri mycot diseas nation center infecti diseas cdc refer adam wg deaver ka cochi sl et al declin childhood haemophilu influenza type b hib diseas hib vaccin era jama broadhurst le erickson rl kellei pw decreas invas haemophilu influenza diseas u. armi children through jama murphi tv white ke pastor p et al declin incid haemophilu influenza type b diseas sinc introduct vaccin jama hicnet medic newslett page volum number april fritzel b plotkin s efficaci safeti haemophilu influenza type b capsular polysaccharid tetanu protein conjug vaccin j pediatr acip haemophilu b conjug vaccin prevent haemophilu influenza type b diseas among infant children two month ag older recommend immun practic advisori committe acip mmwr rr acip diphtheria tetanu pertussi recommend vaccin us other prevent measur recommend immun practic advisori committe acip mmwr rr acip pertussi vaccin acellular pertussi vaccin reinforc booster us supplementari acip statement recommend immun practic advisori committe acip mmwr rr acip pertussi vaccin acellular pertussi vaccin fourth fifth dose dtp seri updat supplementari acip statement recommend immun practic advisori committe acip mmwr rr us trade name commerci sourc identif onli doe impli endors public health servic u. depart health human servic hicnet medic newslett page volum number april dental new intern workshop explor oral manifest hiv infect nidr research digest written jodi dove march nation institut dental research second intern workshop oral manifest hiv infect held januari februari san francisco particip explor issu relat epidemiolog basic molecular virolog mucos immunolog oral clinic present hiv infect workshop organ dr john greenspan dr deborah greenspan depart stomatolog school dentistri univers california san francisco intern steer committe scientif program committe provid guidanc confer drew more than scientist from countri includ asia africa europ central america south america well unit state canada support tor workshop provid nation institut dental research nation cancer institut nation institut allergi infecti diseas nih offic aid research procter gambl compani among topic discuss were epidemiolog hiv lesion ethic profession respons public polici occup issu provis oral care hiv posit popul salivari hiv transmiss mucos immun opportunist infect pediatr hiv infect women' issu recommend recommend emerg from workshop defin associ between appear oral lesion rate progress hiv establish univers terminolog hiv associ oral lesion look more effect treatment oral manifest expand molecular biologi studi understand relationship between hiv infect common oral lesion studi effect hiv therapi oral lesion epidemiolog sinc first intern workshop oral manifest hiv infect conven five year ago epidemiolog hiv infect ha hicnet medic newslett page volum number april radic chang hiv infect detect report larg homosexu bisexu male intraven drug user hemophiliac todai more hiv infect seen heterosexu male femal children adolesc while predomin impact hiv infect ha been felt africa major increas infect rate be seen southeast asia well five hundr thousand case have been report date region more appear all time research continu document epidemiolog oral lesion hairi leukoplakia candidiasi also begin explor relationship between specif oral lesion hiv diseas progress prognosi social polit issu discuss social polit implic hiv infect focus chang public' attitud aid retribut indiscrimin sexual behavior drug us speaker also address health care deliveri hiv infect patient need educ public about what aid how acquir saliva salivari gland confer speaker describ transmiss issu hiv inhibitori activ saliva strength which vari among differ salivari secret whole saliva ha greater inhibitori effect than submandibular secret which turn have greater inhibitori effect than parotid secret research ha shown least two mechan respons salivari inhibitori activ attribut hiv inhibitori effect saliva aggreg agglutin hiv saliva which mai both promot clearanc viru prevent reach target cell direct effect viru target cell other topic discuss were manifest salivari gland diseas hiv infect person current research oral mucos immun pediatr issu pediatr aid recent ha emerg area intens interest earli accur diagnosi proper treatment life expect hiv infect children ha tripl prevent transmiss hiv from mother child mai possibl mani case particularli mother' sero statu known prior give birth periodont gingiv tissu diseas hicnet medic newslett page volum number april oral health research continu explor periodont diseas gingiv found individu hiv infect recommend made workshop includ standard terminolog refin diagnost marker standard studi design proper consider confound variabl result from periodont therapi occup treatment issu occup issu surround treatment hiv infect individu treatment render hiv infect health care profession still command consider attent factor under consider includ cost benefit hiv test patient health care provid transmiss hiv infect revers us mainstream versu dedic facil treatment hiv infect patient confer particip anticip third intern workshop oral manifest hiv infect held five year less proceed from second workshop publish quintess compani late end part internet david stat.com fax bitnet atw h asuacad fidonet amateur packet ax wb tpy wb tpy.az.usa.na 